APAC biotech companies lag US counterparts in venture funding for innovator drugs: GlobalData, Health News, ET HealthWorld
Ophelia Chan
, MSc, Business Fundamentals Analyst, GlobalData, said, "The market saw a decline in investments in 2022 due to market volatility caused by factors such as inflation and geopolitical issues, including the Russia-Ukraine war."
GlobalData Pharma Intelligence Center observed that while APAC headquartered biotechs have historically focused on generics and manufacturing, there seems to be a gradual shift towards investing more in seed and early-stage financing towards innovative drug development.
Asserting that the US continues to lead the biotech venture financing raised for innovator drugs, there is an increasing number of transactions between APAC startups and foreign pharmaceutical investors, Chan concluded by adding, "In addition, the biotechs headquartered in APAC are making strides in innovative developments to secure funding. Despite market volatility affecting both regions, growing interest in APACS innovative technologies from Western pharmaceutical companies could provide future opportunities in this space."
Follow and connect with us on Twitter, Facebook, Linkedin,
Thursday, March 9, 2023 at 10:54 am